查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965779

嬰兒癲癇治療市場－全球產業規模、佔有率、趨勢、機會、預測：依治療層級、藥物類型、劑量、地區和競爭格局分類，2021-2031年

Infantile Spasms Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Drug Type, By Dosage, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球嬰兒癲癇治療市場預計將從 2025 年的 1.4711 億美元成長到 2031 年的 1.8819 億美元，複合年成長率為 4.19%。

該領域的治療方法主要涉及特定藥物療法，例如促腎上腺皮質激素 (ACTH) 和Vigabatrin，這些藥物對於控制癲癇發作和緩解嬰兒的超節律至關重要。由於臨床上迫切需要快速治療以防止神經發育障礙，以及先進的基因篩檢提高了早期診斷率，該市場正在不斷成長。根據美國癲癇協會 2024 年的數據，這種嚴重的疾病影響著約 2000 分之一的兒童，凸顯了全球對專門藥物療法的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 1.4711億美元
市場規模：2031年 1.8819億美元
複合年成長率：2026-2031年 4.19%
成長最快的細分市場 Vigabatrin
最大的市場 北美洲

然而，獲得已通過核准的孤兒藥成本高昂，且監管機構對安全性的嚴格監控，都對市場成長構成了重大障礙。第一線治療藥物可能出現的嚴重毒性反應，需要嚴格的風險管理通訊協定，例如監測視野縮小，這給醫療服務提供者帶來了巨大的後勤挑戰。這些日益成長的財務和行政需求，使得藥物分發流程更加複雜，限制了病患獲得必要治療的機會，尤其是在缺乏改善醫保報銷機制的地區。

市場促進因素

該市場的特點是擁有強大的臨床研發管線，並且針對處於研發階段的癲癇性腦病變和發育性癲癇性腦病變的策略性投資不斷增加。製藥公司已採取優先研發用於治療嬰兒癲癇症候群的後期藥物的策略，產業整合正在顯著推進。例如，2024年10月，H. Lundbeck宣布達成最終協議，將以約26億美元的以金額為準收購Longboard Pharmaceuticals，旨在確保取得用於治療罕見癲癇（例如West症候群）的藥物bexicaserin。這種商業性發展勢頭得益於非營利組織持續的基礎研究資助。 CURE Epilepsy在2024年津貼220萬美元，用於加速科學突破，凸顯了該產業正在發生重大轉變，即透過積極的研發來拓展治療選擇。

同時，由於有利的監管激勵措施和針對關鍵給藥難題而開發的新型製劑，該領域正在取得進展。監管機構正積極推動罕見兒童疾病治療藥物的商業化，透過「孤兒藥認定」賦予生產者顯著的市場獨佔權和優先待遇。這些激勵措施促進了以患者為中心的產品的開發，簡化了看護者的用藥流程。例如，在2024年6月的新聞稿中，Pyrus Pharmaceuticals宣布美國FDA已核准Vigafide上市，這是一種根據孤兒藥認定計畫開發的嬰兒癲癇治療藥物。這是首個可取代複雜粉末的即用型口服液製劑。這項進展表明，法規結構正在直接支持最佳化治療方法的引入，從而提高患者的用藥依從性。

市場挑戰

獲得孤兒藥物已通過核准的高昂成本，加上嚴格的監管安全監測，對市場擴張構成了重大障礙。這些財務和行政負擔直接阻礙了市場成長，限制了患者獲得必要治療的機會。一線療法的高昂價格給醫療預算和保險公司帶來了沉重負擔，常常導致保險拒付和核准延遲。此外，對於具有嚴重毒性的藥物，必須進行嚴格的風險評估，這造成了巨大的後勤障礙，要求醫療機構投入大量資源用於安全監測項目，使藥物分發更加複雜，並限制了能夠開具這些特殊藥物的醫療機構數量。

保險保障不足進一步加劇了這種困境，將經濟負擔轉嫁到家庭身上。根據美國國家罕見疾病組織 (NORD) 2024 年的報告，美國有 22 個州因處方藥自付費用保障政策極度匱乏而被評為 C 級，另有 3 個州因完全沒有保障而被評為 F 級。這種缺乏全面經濟保障的情況意味著，即使有有效的治療方法，經濟負擔也會阻礙患者開始治療，從而有效地縮小了商業性可行性的患者群體。

市場趨勢

精準醫療和基因譜分析的應用正在從根本上重塑治療格局，將治療模式從頻譜類固醇轉向病因特異性干預。隨著我們對嬰兒癲癇症候群遺傳結構的理解不斷加深，臨床醫生越來越重視基因組檢測，以便在啟動標準治療之前識別可治療的代謝或遺傳病因。這一趨勢正在推動標靶治療的發展，這些療法作用於特定的生物通路，而不僅僅是抑制症狀。根據發表在2024年2月《基因》（Genes，巴塞爾）雜誌上題為「嬰兒癲癇症候群的遺傳進展和精準醫療的潛力」的論文，研究人員目前已發現70多個與此症候群相關的單基因致病變異，這一發現正在加速對mTOR抑製劑等標靶藥物的臨床需求。

同時，數位癲癇監測與人工智慧的融合正在變革診斷通訊協定和療效追蹤，直接應對識別細微癲癇發作的挑戰。新型機器學習驅動的診斷工具正在開發中，用於分析家庭影片數據，從而實現快速遠端評估和早期治療，這對於維持神經發育功能至關重要。這項技術進步透過減少長期住院期間對視訊腦電圖監測的依賴並最大限度地減少診斷延誤，擴大了商業性可行性的患者群體。根據2025年1月發布的CURE Epilepsy報告（基於2024年美國癲癇協會年會上公佈的研究結果），一種新開發的AI模型透過分析看護者錄製的影片，在檢測嬰兒癲癇發作方面展現出85%的準確率。這凸顯了數位醫療在簡化患者識別和管理方面的潛力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：嬰兒癲癇治療藥物的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 治療分類（抗癲癇藥、皮質類固醇、其他）
    • 依藥物類型（Vigabatrin、促腎上腺皮質激素、其他）
    • 劑型（固態、液體）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美嬰兒癲癇治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲嬰兒癲癇治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區嬰兒癲癇治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲嬰兒癲癇治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美嬰兒癲癇治療藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球嬰幼兒癲癇治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18993

The Global Infantile Spasms Therapeutics Market is projected to expand from USD 147.11 Million in 2025 to USD 188.19 Million by 2031, reflecting a compound annual growth rate of 4.19%. Therapeutics in this sector primarily involve specific pharmaceutical interventions, such as adrenocorticotropic hormone and vigabatrin, which are essential for arresting epileptic spasms and resolving hypsarrhythmia in infants. The market is driven by the urgent clinical need for rapid treatment to prevent neurodevelopmental regression, along with rising early diagnosis rates enabled by advanced genetic screening. Data from the Epilepsy Alliance America in 2024 indicates that this severe disorder affects approximately one in every 2,000 children, underscoring a consistent global demand for specialized pharmacological management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 147.11 Million
Market Size 2031USD 188.19 Million
CAGR 2026-20314.19%
Fastest Growing SegmentVigabatrin
Largest MarketNorth America

However, market growth faces significant hurdles due to the high acquisition costs of approved orphan drugs and the rigorous safety monitoring enforced by regulatory agencies. The severe toxicity associated with primary treatments necessitates strict risk management protocols, such as monitoring for visual field constriction, which imposes substantial logistical challenges on healthcare providers. These elevated financial and administrative demands complicate the distribution process and restrict patient access to necessary therapies, particularly in regions that lack comprehensive reimbursement frameworks.

Market Driver

The market is defined by a robust clinical pipeline and increasing strategic investments focused on developmental and epileptic encephalopathies. Pharmaceutical companies are prioritizing late-stage assets for Infantile Epileptic Spasms Syndrome, resulting in significant industry consolidation. For example, H. Lundbeck A/S announced a definitive agreement in October 2024 to acquire Longboard Pharmaceuticals for an equity value of roughly $2.6 billion, aiming to secure access to bexicaserin for rare epilepsies like West syndrome. This commercial momentum is supported by continued non-profit funding for foundational research; CURE Epilepsy awarded $2.2 million in grants in 2024 to accelerate scientific breakthroughs, highlighting a decisive industry shift toward expanding therapeutic options through aggressive research and development.

Concurrently, the sector is advancing due to favorable regulatory incentives and the creation of novel formulations that solve critical administration issues. Regulatory bodies actively promote the commercialization of treatments for rare pediatric diseases via Orphan Drug Designations, offering manufacturers crucial market exclusivity and benefits. These incentives have fostered the development of patient-centric products that simplify dosing for caregivers. For instance, Pyros Pharmaceuticals announced in a June 2024 press release that the U.S. FDA approved Vigafyde, the first ready-to-use oral solution for infantile spasms developed under the Orphan Drug pathway to replace complex powder formulations. Such progress illustrates how regulatory frameworks directly support the launch of optimized therapies that improve patient compliance.

Market Challenge

The prohibitive acquisition costs of approved orphan drugs, combined with stringent regulatory safety monitoring, constitute a formidable barrier to market expansion. These financial and administrative burdens directly hamper growth by restricting patient access to essential therapies. The high price of first-line treatments places immense strain on healthcare budgets and insurance providers, often leading to coverage denials or delayed approvals. Furthermore, the rigorous risk evaluation mandated for drugs with severe toxicity profiles creates significant logistical hurdles, requiring healthcare providers to dedicate substantial resources to safety monitoring programs, which complicates distribution and limits the number of centers capable of prescribing these specialized medications.

This challenging environment is further exacerbated by inadequate insurance protections that transfer economic liability to families. According to the National Organization for Rare Disorders in 2024, twenty-two U.S. states received a C grade for maintaining only minimal out-of-pocket prescription drug cost protection policies, while three states received an F grade for having absolutely no such protections in place. This lack of comprehensive financial safeguards means that even when effective therapeutics are available, the economic burden can prevent therapy initiation, effectively reducing the commercially addressable patient population.

Market Trends

The adoption of precision medicine and genetic profiling is fundamentally reshaping the therapeutic landscape by shifting treatment paradigms from broad-spectrum corticosteroids to etiology-specific interventions. As the understanding of the genetic architecture of Infantile Epileptic Spasms Syndrome deepens, clinicians are increasingly prioritizing genetic panels to identify treatable metabolic or genetic causes before initiating standard therapies. This trend is driving the development of targeted therapeutics that address specific biological pathways rather than merely suppressing symptoms. According to an article in Genes (Basel) from February 2024, titled 'Genetic Advancements in Infantile Epileptic Spasms Syndrome and Opportunities for Precision Medicine,' researchers have now identified over 70 single gene pathogenic variants associated with the syndrome, a discovery that is accelerating the clinical demand for targeted agents such as mTOR inhibitors.

Simultaneously, the integration of digital seizure monitoring and artificial intelligence is transforming diagnostic protocols and efficacy tracking, directly addressing the challenge of identifying subtle spasms. Novel diagnostic tools leveraging machine learning are being developed to analyze home video data, allowing for rapid remote assessment and earlier therapy initiation, which is critical for preserving neurodevelopmental function. This technological evolution reduces the dependency on prolonged inpatient video-EEG monitoring and expands the commercially addressable patient population by minimizing diagnostic delays. According to a January 2025 CURE Epilepsy report on findings presented at the 2024 American Epilepsy Society Annual Meeting, a newly developed AI model for analyzing caregiver-recorded videos demonstrated an accuracy of 85% in detecting infantile spasms, highlighting the potential of digital health to streamline patient identification and management.

Key Market Players

  • Merck KGaA
  • Novartis AG
  • Sanofi SA
  • Pfizer Inc
  • Johnson & Johnson
  • Abbott Laboratories Inc
  • Teva Pharmaceutical Industries Ltd
  • Bausch Health Companies Inc.
  • AstraZeneca PLC
  • GSK PLC

Report Scope

In this report, the Global Infantile Spasms Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Infantile Spasms Therapeutics Market, By Therapeutic Class

  • Anticonvulsants
  • Corticosteroids
  • Others

Infantile Spasms Therapeutics Market, By Drug Type

  • Vigabatrin
  • Adrenocorticotropic Hormone
  • Others

Infantile Spasms Therapeutics Market, By Dosage

  • Solid
  • Liquid

Infantile Spasms Therapeutics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Infantile Spasms Therapeutics Market.

Available Customizations:

Global Infantile Spasms Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Infantile Spasms Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
    • 5.2.2. By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others)
    • 5.2.3. By Dosage (Solid, Liquid)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Infantile Spasms Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapeutic Class
    • 6.2.2. By Drug Type
    • 6.2.3. By Dosage
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Infantile Spasms Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapeutic Class
        • 6.3.1.2.2. By Drug Type
        • 6.3.1.2.3. By Dosage
    • 6.3.2. Canada Infantile Spasms Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapeutic Class
        • 6.3.2.2.2. By Drug Type
        • 6.3.2.2.3. By Dosage
    • 6.3.3. Mexico Infantile Spasms Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapeutic Class
        • 6.3.3.2.2. By Drug Type
        • 6.3.3.2.3. By Dosage

7. Europe Infantile Spasms Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapeutic Class
    • 7.2.2. By Drug Type
    • 7.2.3. By Dosage
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Infantile Spasms Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapeutic Class
        • 7.3.1.2.2. By Drug Type
        • 7.3.1.2.3. By Dosage
    • 7.3.2. France Infantile Spasms Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapeutic Class
        • 7.3.2.2.2. By Drug Type
        • 7.3.2.2.3. By Dosage
    • 7.3.3. United Kingdom Infantile Spasms Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapeutic Class
        • 7.3.3.2.2. By Drug Type
        • 7.3.3.2.3. By Dosage
    • 7.3.4. Italy Infantile Spasms Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapeutic Class
        • 7.3.4.2.2. By Drug Type
        • 7.3.4.2.3. By Dosage
    • 7.3.5. Spain Infantile Spasms Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapeutic Class
        • 7.3.5.2.2. By Drug Type
        • 7.3.5.2.3. By Dosage

8. Asia Pacific Infantile Spasms Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapeutic Class
    • 8.2.2. By Drug Type
    • 8.2.3. By Dosage
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Infantile Spasms Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapeutic Class
        • 8.3.1.2.2. By Drug Type
        • 8.3.1.2.3. By Dosage
    • 8.3.2. India Infantile Spasms Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapeutic Class
        • 8.3.2.2.2. By Drug Type
        • 8.3.2.2.3. By Dosage
    • 8.3.3. Japan Infantile Spasms Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapeutic Class
        • 8.3.3.2.2. By Drug Type
        • 8.3.3.2.3. By Dosage
    • 8.3.4. South Korea Infantile Spasms Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapeutic Class
        • 8.3.4.2.2. By Drug Type
        • 8.3.4.2.3. By Dosage
    • 8.3.5. Australia Infantile Spasms Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapeutic Class
        • 8.3.5.2.2. By Drug Type
        • 8.3.5.2.3. By Dosage

9. Middle East & Africa Infantile Spasms Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapeutic Class
    • 9.2.2. By Drug Type
    • 9.2.3. By Dosage
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Infantile Spasms Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapeutic Class
        • 9.3.1.2.2. By Drug Type
        • 9.3.1.2.3. By Dosage
    • 9.3.2. UAE Infantile Spasms Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapeutic Class
        • 9.3.2.2.2. By Drug Type
        • 9.3.2.2.3. By Dosage
    • 9.3.3. South Africa Infantile Spasms Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapeutic Class
        • 9.3.3.2.2. By Drug Type
        • 9.3.3.2.3. By Dosage

10. South America Infantile Spasms Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapeutic Class
    • 10.2.2. By Drug Type
    • 10.2.3. By Dosage
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Infantile Spasms Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapeutic Class
        • 10.3.1.2.2. By Drug Type
        • 10.3.1.2.3. By Dosage
    • 10.3.2. Colombia Infantile Spasms Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapeutic Class
        • 10.3.2.2.2. By Drug Type
        • 10.3.2.2.3. By Dosage
    • 10.3.3. Argentina Infantile Spasms Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapeutic Class
        • 10.3.3.2.2. By Drug Type
        • 10.3.3.2.3. By Dosage

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Infantile Spasms Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Merck KGaA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. Sanofi SA
  • 15.4. Pfizer Inc
  • 15.5. Johnson & Johnson
  • 15.6. Abbott Laboratories Inc
  • 15.7. Teva Pharmaceutical Industries Ltd
  • 15.8. Bausch Health Companies Inc.
  • 15.9. AstraZeneca PLC
  • 15.10. GSK PLC

16. Strategic Recommendations

17. About Us & Disclaimer